Setting the Finish Line

• To start, what is the enrollment target and regulatory filing milestone you need this study to support? Options: First patient in within 8 weeks, First patient in within 12 weeks, Primary completion by a fixed date, Regulatory submission window is the driving deadline, Other
• Tell me about the protocol stage and any planned amendments that could affect startup timing or site eligibility.
• When you think about executive pressure on this program, which single outcome would satisfy leadership most quickly? Options: First patient in on original target, Substantial country coverage by X date, Regulatory readiness for filing, Cost predictability, Other
• Which internal owners will need to be involved from regulatory, legal, finance, and clinical operations during startup? Options: Regulatory lead, Head of Clinical Operations, General Counsel or Legal, Finance approver, Project manager/PMO, Local country lead, Other
• Describe the last trial your team ran that met enrollment on schedule, and what operational differences made it succeed.

Where Time Slips Away

• If the activation runs even two weeks late, which downstream deadline or regulatory milestone is most at risk? Options: Primary completion milestone, Regulatory submission date, Investor reporting milestone, Operational budget window, Other
• On recent studies, where did the largest startup delays occur: regulatory approvals, contracting, site paperwork, or site training? Options: Regulatory approvals, Contracting and budgets, Site qualification and paperwork, Investigator training and delegation logs, Other
• How long does a typical local ethics or IRB approval take in your core countries today? Options: Under 4 weeks, 4 to 8 weeks, 8 to 12 weeks, More than 12 weeks, We do not have reliable data
• What single timing failure would make you halt or re-scope the program immediately?
• Which mitigation steps have you tried when timelines slipped, and which actually shortened time to activation? Options: Parallel contracting and regulatory submission, Use of central IRB where possible, Fast-track site training, Prioritized site lists, None of the above, Other

Protocol and Regulatory Boundaries

• Do any protocol requirements constrain which countries or sites can participate, such as specialized labs, imaging timing, or complex assay logistics? Options: Yes, specialized labs required, Yes, complex imaging or timing, Yes, restricted by investigational product handling, No significant constraints, Unsure
• Describe the country-specific regulatory hurdles that have surprised your team on past programs and how they were resolved.
• Who currently owns the regulatory strategy, and how often does that owner consult clinical operations during startup planning? Options: Regulatory team, Clinical operations, Project team jointly, External consultant, Not yet assigned
• Identify the single regulatory outcome that would force you to pause startup in a country. Options: Regulatory rejection of the dossier, Mandated protocol change, Local import permit denied, Significant safety hold, Other
• Tell me about your preferred dossier and ethics submission templates, and whether translations or notarizations are already available. Options: Templates and translations ready, Templates ready, translations needed, Templates in development, No templates available, Other

How You Really Find and Qualify Sites

• When you select a site, what evidence do you insist on to believe it will recruit to target? Options: Past enrollment in similar indication, PI engagement and bandwidth, Active patient registries, Diagnostic capacity confirmed, Other
• List the site-level metrics you use to forecast screen rates and say whether that data lives centrally or with local teams. Options: Historical monthly enrollments, Screen failure rate, Average time to first patient in, Number of eligible patients per month, Other
• Who at the site signs budgets and contracts, and how predictable is their approval timeline on average? Options: Principal investigator, Hospital legal/contracting office, Clinical research office, Site finance, Varies by country
• If the top five candidate sites show lower-than-expected screen rates in feasibility, would you pause selection, reduce targets, or expand footprint? Options: Pause and re-evaluate, Reduce targets per site, Expand to additional sites/countries, Adjust inclusion criteria, Other
• Recall the last site activation that went smoothly, what operational actions made that possible from a startup perspective?

Money, Contracts, and the People Who Approve Them

• Identify the contractual term that, if missing or delayed, most often blocks site activation for you. Options: Budget approval, PI signature, Indemnity language, Data sharing addendum, Other
• Name the internal approvers who must sign commercial terms before contracting starts and how many review cycles they typically require. Options: 1 cycle, 2 cycles, 3 or more cycles, Varies widely, Not sure
• How long does finance typically take to approve site budgets once the proposed costs are submitted? Options: Under 1 week, 1 to 2 weeks, 2 to 4 weeks, More than 4 weeks, Not applicable
• Suppose legal rejects a sponsor-favorable indemnity clause, would that stop the program or is an alternative clause acceptable? Options: Stop the program, Accept alternative clause, Escalate for executive decision, Not sure
• Select the payment milestone cadence that feels acceptable for this program. Options: Single upfront payment, Split at activation and first patient in, Monthly per-site invoicing, Milestone-based tied to enrollment, Other

The Other Options You Are Weighing

• List the external providers and internal options you are actively evaluating as alternatives to outsourcing startup. Options: Incumbent CRO, New CRO partner, Internal build or dedicated team, Hybrid model, No alternative identified
• What would need to be true about staying with your current approach for you to decide not to change vendors? Options: Faster timelines proven, Lower overall cost, Improved reporting visibility, Stronger regulatory experience, Other
• Name any internal advocates for a build-it-in-house option and describe the resources they proposed.
• Assume the incumbent matches the activation timeline we propose, what additional factor would still make you switch to a new partner? Options: Better site network, Transparent milestone tracking, Faster contracting, Lower risk of regulatory delay, Other
• Choose the reasons that explain why you might stay with the incumbent or internal team today. Options: Lower cost, Existing relationships with sites, Data continuity, Perceived lower risk, No internal bandwidth to change, Other

Operational Readiness and Constraints

• Point to the single system integration or portal access that is nonnegotiable for real-time milestone tracking. Options: CTMS access, Sponsor portal credentials, eTMF upload access, No integration required, Other
• Does your IT team own API access or will a third party manage connections for data exchange? Options: IT owns API access, Third party manages connections, No API available today, Undecided
• Provide the name and role of the person responsible for releasing data and performing eTMF uploads during startup.
• Confirm whether you can commit to a remediation plan within 3 weeks if source data or systems are fragmented, or will that delay kickoff? Options: Can commit to 3-week remediation, Would delay kickoff, Needs further assessment
• Select which infrastructure items are in place today for rapid startup. Options: Central eTMF, CTMS access for vendor, Regulatory dossier templates, Translation vendor contract, Local lab service agreements, None of the above

How You Will Declare Success

• Declare the primary activation KPI that would cause you to sign mutual acceptance within weeks rather than months. Options: First patient in per site within X weeks, Sites activated per month, Regulatory approvals in target countries, Contract and budget sign-off for top sites, Other
• Choose the enrollment curve you would accept as proof of feasibility: steady ramp, early peak, or front-loaded enrollment. Options: Steady ramp, Early peak then plateau, Front-loaded enrollment, Other
• Provide the roles that must sign off on acceptance criteria and milestone payments for activation to be official.
• Explain the contractual remedy or program pause you would expect if agreed milestones are missed twice across critical sites.
• Tick the KPIs you track today for startup visibility. Options: Sites activated per month, Time from site selection to FPI, Ethics approval lead time, Contract cycle time, Screen failure rate, Other

Next Steps and Hard Decisions

• Should a pilot meet your top KPI, what would stop you from executing a full program with an outside partner this quarter? Options: Budget not approved, Internal politics, Lack of executive buy-in, Regulatory uncertainty, Other
• Inventory the internal resources you can commit to a 6 to 12 week activation effort immediately.
• Detail the day-to-day liaison role and backup contacts we should expect to work with during startup.
• Outline the alternative approval path or scope reduction you would accept if budgetary approval takes longer than your target. Options: Use phased country activation, Deploy limited site list, Move to cost-sharing model, Escalate to executive committee, Other
• Mark which of these next-step commitments you are prepared to make in the next two weeks. Options: Provide named preliminary site list, Confirm budget and payment milestones, Grant portal access to vendor, Approve regulatory dossier for submission, Schedule startup workshop, None of the above

• Startup Pathway Workshop

• Confirm the current state and its cost
• You confirm the restated current state and accept the described cost to your filing timeline as accurate.
• Deliver a tailored activation pathway document with country-level milestones, an estimated compressed time-to-activation, and identified decision gates within five business days.
• You confirm the presented activation pathway demonstrably reduces the regulatory and contracting delays you described.
• Present the validated activation pathway
• Provide the final protocol version, list of target countries and priority sites, and any known regulatory constraints within three business days.
• Simulate compressed timeline and risk trade-offs
• You agree to the seller deliverable and the buyer inputs required to produce a country- and site-level pathway for decision.
• Confirm the buying committee members and target decision date for pathway acceptance.
• Validate the mapping to your needs
• Agree next steps and required inputs

• Startup Pathway Workshop
• Startup Pathway Workshop Deck
• Startup Pathway Solution Brief

• meeting
• slides
• document

• Regulatory application preparation and submission
• Central ethics committee submission and management
• Local IRB/ethics coordination and approval tracking
• Site identification and feasibility assessments
• Site qualification and initiation visits
• Site contracting, budget negotiation, and finalization
• Site regulatory binder and startup documentation assembly
• Investigator and coordinator training and certification
• Startup milestone tracking portal configuration and reporting
• Regulatory document translation and localization
• Investigational product release and site supply coordination
• Site payment setup and budget disbursement management

Regulatory application preparation and submission

• Identify which regulatory authority you will submit to first (for example the national Competent Authority for a Clinical Trial Authorization) Options: Single national authority, Multiple national authorities simultaneously, Centralized regional procedure, Unclear — need recommendation
• Estimate how many countries are included in your planned regulatory submission Options: 1, 2-5, 6-15, 16+
• Specify what regulatory pathway you expect for initial approval (for example Clinical Trial Authorization, notification, expedited review) Options: Clinical Trial Authorization, Notification, Expedited review pathway, Undecided — need guidance
• Select which document set you must include in the dossier for submission (for example protocol, Investigator Brochure, manufacturing batch release, safety reports) Options: Protocol, Investigator Brochure (IB), Manufacturing/batch release documents, Safety aggregate reports, Other regulatory documents
• List the languages your regulatory documents must be filed in for each target country
• What acceptance criteria will you require for regulatory submission completeness (for example required document checklist, validated dossier checklist, target validation date)

Central ethics committee submission and management

• Which central ethics committee will you submit the master application to (name or jurisdiction)
• Do you have an approved master informed consent form (ICF) template ready for central submission Options: Yes, No, Draft — needs review
• Name the role responsible on your team for responding to central committee queries and providing safety updates
• When do you target central ethics committee review to be completed relative to regulatory authorization Options: Before regulatory submission, Concurrent with regulatory submission, After regulatory authorization
• Are there specific patient-facing materials you will submit for ethics review beyond the ICF (for example recruitment ads, screening scripts) Options: Yes — recruitment materials, Yes — advertising/website copy, No
• Which timeline constraints or central committee meeting dates do you need us to work around for submission scheduling

Local IRB/ethics coordination and approval tracking

• Estimate how many local institutional review boards (IRBs) or ethics committees you will need to submit to separately Options: None (central only), 1-5, 6-15, 16+
• Which of your target sites will require independent IRB review due to local regulations or hospital policy (list sites or site types)
• Must local IRBs at your sites receive translated ICFs with certified translations and stamped signatures Options: Yes — certified translations required, Translation without certification acceptable, Varies by site — needs assessment
• Provide the contact role you expect at each site for local IRB communications
• What is your preferred method to capture local IRB approval documents (scanned stamped letter, e-submission receipt, portal upload to eTMF) Options: Scanned stamped letter, E-submission receipt, Direct upload to eTMF, Paper binder only
• Are there local response timelines for IRB queries at your sites (for example 10 business days) that we should include in the plan Options: Yes — list timelines, No, Unknown — need assessment

Site identification and feasibility assessments

• How many sites do you want assessed for feasibility in this initial activation scope Options: 1-5, 6-15, 16-50, 50+
• Which feasibility criteria are highest priority for you (patient population, prior enrollment performance, onsite diagnostic equipment, lab capacity) Options: Target patient population and prevalence, Prior enrollment performance on similar trials, Onsite diagnostic/imaging capability, Laboratory and sample handling capacity, Staff availability and competing trials, Regulatory/ethics responsiveness
• Will you require source document availability or historic SDV (source data verification) rates from sites as part of feasibility assessments Options: Yes — SDV history required, No — not required, Optional
• Which electronic systems at your sites (for example local electronic health records) must be documented or considered during feasibility
• Are there country-specific feasibility constraints you need us to map (for example import restrictions, consent law differences, data residency) Options: Yes — list constraints, No, Unknown — need assessment
• Provide your recruitment projections per site for the first 3 months and first 6 months

Site qualification and initiation visits

• How many initiation visits do you require per site and do you prefer remote, onsite, or hybrid site initiation visits (SIVs) Options: Onsite only, Remote only, Hybrid (remote + onsite), Depends on site risk assessment
• Which deliverables must you verify during site qualification (for example signed protocol, investigator CVs, ICH-GCP certificates, delegation of authority log, laboratory certifications) Options: Signed protocol, Investigator CVs and licenses, ICH-GCP certificates, Delegation of authority log, Laboratory certification/calibration records, Facility/equipment checklist
• Will you require historical enrollment and performance metrics from sites (for example screen-to-randomization ratio) as part of qualification Options: Yes, No, Optional
• Specify the owner role you expect for scheduling and conducting site initiation visits (SIVs)
• What defines acceptance for site activation at the site level for you (for example ethics approval dated, contract signed, training completed)
• How would you like corrective actions from qualification tracked and verified (CAPA log with owner, follow-up visit, evidence in eTMF) Options: Corrective action plan with owner and due date, Follow-up onsite visit, Evidence upload to eTMF, Other

Site contracting, budget negotiation, and finalization

• What is your preferred contract model for site agreements (fee-for-service, milestone-based, hybrid) Options: Fee-for-service, Milestone-based, Hybrid, Need recommendation
• Do you have a standard budget template you want us to use or do your sites require bespoke budgets Options: Standard template available, Sites require bespoke budgets, Combination — standard + local adjustments
• Which cost elements must you include in site budgets (for example per-visit fees, overhead, patient travel, lab costs, imaging fees) Options: Per-visit fees, Procedure fees (imaging, labs), Overhead/indirect costs, Patient travel reimbursement, Screening and enrollment fees, Storage and handling of IMP
• Provide the role or person on your side who will supply authorized signature and payer details for institutional contracts and the documentation they will require
• Are local tax, VAT, or gross-up requirements applicable for site payments in your target countries Options: Yes — tax/VAT applies, No, Varies by country — needs assessment
• What turnaround time do you expect for contract execution once budget is agreed (in days) Options: 7 days, 14 days, 21-30 days, Custom

Site regulatory binder and startup documentation assembly

• What documents must you include in the site regulatory binder at activation (for example signed protocol, ICF, investigator CVs, ICH-GCP certificates, delegation log) Options: Signed final protocol, Final ICF, Investigator CVs and licenses, ICH-GCP training certificates, Delegation of authority log, Lab certifications
• Are eTMF upload standards and a specific folder structure required by you for site document delivery Options: Yes — provide structure and metadata requirements, No — paper binder only, Hybrid — both eTMF and paper
• Which signature and version-control standards do you require for binder documents (for example wet-signed PDFs, e-signature with audit trail, stamped copies) Options: Wet-signed PDFs, E-signature with audit trail, Stamped scanned copies, Other
• Designate the owner you expect to be responsible for assembling and uploading the site binder to the eTMF
• Do you require local language versions of the ICF or protocol in the binder at activation for any of your sites Options: Yes — certified translations required, No — English accepted, Depends on site/regulator
• How will you validate completeness of the site binder (for example required-document checklist, minimum completeness percentage threshold) Options: Checklist with required documents count, Minimum percentage completeness threshold, Manual QA review

Investigator and coordinator training and certification

• Which training curriculum do your investigators and coordinators require (for example protocol training, ICH-GCP, IMP handling, site-specific SOPs) Options: Protocol training, ICH-GCP, IMP handling and accountability, Site SOPs and pharmacy procedures, Other
• How will you verify training completion at sites (for example LMS completion record, scanned certificates uploaded to eTMF, recorded attendance) Options: LMS completion record, Scanned certificates in eTMF, Recorded session attendance list, Other
• Will you need training delivered in multiple languages or localized versions of protocol training for your sites Options: Yes — multilingual required, No — English only, Depends on country
• Assign who will deliver investigator meetings or recorded protocol walk-throughs for your study
• Are competency assessments (for example quizzes or observed demonstrations) required by you before a site can be activated Options: Yes — quizzes/assessments required, No — certificate only, Selective for high-risk procedures
• What validity period do you accept for required GCP certificates for activation (for example within 2 years) Options: Within 1 year, Within 2 years, Within 3 years, No expiry requirement specified

Startup milestone tracking portal configuration and reporting

• Which portal reports are essential for your startup milestone tracking (for example IRB/ethics approvals, contracts signed, training complete, target activation date per site) Options: IRB/ethics approvals dashboard, Contracts executed tracker, Training completion report, Target activation date per site, Custom KPI(s)
• Do you require role-based dashboards and access controls for different stakeholders on your team Options: Yes — full role-based dashboards, No — single view only, Limited role-based views
• Do you require single sign-on integration for the portal with your identity provider Options: Yes — SSO required, No — portal credentials acceptable, Prefer SSO but optional
• Which milestone notifications would you like automated to your team (for example site approved, contract executed, IMP shipped) Options: IRB/ethics approval received, Contract executed, Training completed, IMP shipped to site, Site activated (ready to screen)
• What acceptance criteria will confirm portal configuration is complete for you (for example report templates in place, test data loaded, user access validated)
• How frequently do you want automated startup reports delivered to your team (daily, weekly, custom cadence) Options: Daily, Weekly, Bi-weekly, Monthly, Custom schedule

Regulatory document translation and localization

• Which languages do you require for translation of protocol, ICF, training materials, and regulatory cover letters
• Must translations for your target countries be certified and notarized by a qualified translator Options: Yes — certification/notarization required, No — certified translation not required, Varies by country — needs mapping
• Who on your team will review and approve localized ICFs and protocol translations before submission Options: Medical lead, Local principal investigator, Local legal counsel, Other
• Are there country-specific formatting or content requirements for ICFs you want implemented (for example font size, mandatory consent elements) Options: Yes — list requirements, No, Unknown — need assessment
• What turnaround times do you require for translations per document (for example 5 business days per ICF) Options: 2-3 business days, 4-7 business days, 8-14 business days, Custom
• Do you require reconciliation between translated and source language documents with tracked changes for auditing Options: Yes — reconciliation required, No, Optional

• Mutual Confidentiality Agreement (NDA)
• Master Services Agreement (MSA)
• Statement of Work (SOW)
• Milestone Payment Schedule
• Resource Commitment Schedule
• Site Activation Acceptance Criteria Annex
• Change Order Agreement
• Termination and Transition Agreement
• Subcontractor and Data Subprocessor Annex
• HIPAA Business Associate Addendum (BAA) (conditional)

• Go-live Health Check (weeks 1-4)
• First Measurement Review (weeks 4-10)
• Acceptance Gate — Startup Outcomes Decision (around day 90)
• Handover and Lessons Learned (post-acceptance)
• Quarterly Operational Review (ongoing)

• Create the ongoing support ticket queue and document SLA response and resolution expectations.
• Produce a documented pass/fail result for each Acceptance Scope criterion recorded in Activation Scope.
• Capture the formal acceptance decision and the required acceptance record or signatory for the journey.
• Agree remediation actions and verification dates for any conditional acceptance items.
• Publish the Acceptance Gate record and attach all supporting evidence to the shared workspace.
• Log remediation actions for conditional items with deadlines in the issue tracker and schedule the verification checkpoint.
• Archive all startup artifacts (regulatory submissions, ethics approvals, executed contracts, training logs) to the agreed repository.
• Confirm final outcomes and evidence
• All conditional acceptance remediation items are confirmed closed and evidence is attached to the archive.
• A documented lessons-learned summary and updated runbook are published to the shared workspace.
• A named shared support channel and SLA expectations are confirmed and communicated.
• Publish the lessons-learned document and updated runbook to the shared workspace.
• Re-confirm success criteria and owners
• Schedule the 30-day post-handover verification checkpoint and invite operational owners.
• Enrollment performance vs plan
• Confirm whether the current quarterly enrollment rate is on track with the plan recorded in Activation Scope and surface corrective priorities if not.
• Reduce the open post-startup issue count for high-impact items within the next quarter through agreed actions.
• Ensure support SLAs are being met and any escalations have a resolution path and timeline.
• Publish the quarterly enrollment and issue-backlog report with prioritized remediation items and target dates.
• Open targeted tickets for the top three operational priorities with completion dates in the shared issue tracker.
• Confirm next quarterly review date and required pre-read materials to be circulated one week prior.
• All active sites have confirmed portal access and named primary site contacts documented.
• High-priority blockers are logged with remediation actions and deadlines.
• Training completion and basic adoption signals are above the agreed minimum engagement thresholds for this early window.
• Publish and distribute the validated site access and contact list to the shared workspace.
• Log each high-priority blocker in the shared issue channel with a target resolution date.
• Circulate training completion report and any remediation plans for sites below the minimum threshold.
• Present outcome data vs Activation Scope targets
• Determine whether site activation and enrollment pace meet the targets recorded in Activation Scope, with documented variance where they do not.
• Agree a prioritized set of corrective actions with deadlines that will return metrics toward the Activation Scope targets before the Acceptance Gate.
• Confirm required evidence and timing for the Acceptance Gate decision.
• Publish the metric dashboard extract and gap analysis for async review prior to the Acceptance Gate meeting.
• Create a prioritized remediation plan with task-level deadlines and publish to the shared issue channel.
• Collect site-level corrective action commitments and expected completion dates for evidence submission.
• Restate Acceptance Scope and numeric targets
• Capture lessons learned
• Present outcome evidence per criterion
• Operational metric detailed review
• Deployment and configuration validation
• Open issue backlog and burn-down
• Update runbooks and handover artifacts
• Early adoption signals
• Record pass/fail per criterion
• Root-cause analysis for gaps
• Support SLA and escalation review
• Establish the shared support channel and SLA expectations
• Prioritize operational work for the next quarter
• Corrective action planning
• Formal acceptance decision and signatory capture
• Blockers and mitigation plan
• Agree remediation items and resolution timeline
• Confirm timeline to Acceptance Gate
• Plan a short verification checkpoint
• Short summary and next steps
• Agree next checkpoint